Current companies developing γδ T cell-based immunotherapies
| Company | γδ T cell type | Allogeneic vs. autologous | Targeting strategy/engineering |
|---|---|---|---|
| GammaCell Biotechnologies | Vδ2 | Autologous/allogeneic | Unmodified |
| Hebei Senlang Biotechnology | Vδ2 | Autologous | CAR/αβTCR |
| Incysus Therapeutics | Vδ2 | Autologous | Engineered for chemo-resistance |
| Adicet Bio, Inc. | Vδ1 | Allogeneic | CAR |
| Beijing Doing Biomedical | Vδ2 | Allogeneic | Unmodified/CAR |
| Cytomed Therapeutics | Vδ2 | Allogeneic | CAR |
| GammaDelta Therapeutics | Vδ1 | Allogeneic | CAR |
| Immatics | Vδ2 | Allogeneic | αβTCR |
| PhosphoGam Inc. | Vδ2 | Allogeneic | Unmodified |
| TC BioPharm | Vδ1/Vδ2 | Autologous/allogeneic | Unmodified/CAR |
| Imcheck Therapeutics | Vδ2 | Autologous (in vivo) | Vδ2 activation with BTN3A |
| Lava Therapeutics | Vδ2 | Autologous (in vivo) | Activated Vδ2 with BiTE |
| PersonGen BioTherapeutics | γδ T | Allogeneic | TAA3-UCAR, CD7 UCAR |
| Expression Therapeutics | Vδ2 | Allogeneic | Unmodified/CAR |
UCAR: universal CAR
Note. Adapted from "Cancer immunotherapy with γδ T cells: many paths ahead of us", by Kabelitz D, Serrano R, Kouakanou L, Peters C, Kalyan S. Cell Mol Immunol. 2020;17:925–39 (https://www.nature.com/articles/s41423-020-0504-x). CC-BY.